XML 15 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:    
Net Income (Loss) $ (18,192) $ (11,880)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 122 83
Stock-based compensation 4,115 2,433
Accretion on marketable securities, net (1,229) 0
Changes in operating assets and liabilities:    
Prepaid expenses and other assets (43) 1,530
Accounts payable, accrued expenses and other liabilities (6,906) (2,022)
Right-of-use assets and lease liabilities, net 105 9
Net cash used in operating activities (22,028) (9,847)
Cash flows from investing activities:    
Purchases of marketable securities (11,791) 0
Sales and maturities of marketable securities 30,000 0
Purchases of property and equipment (136) (41)
Net cash provided by (used in) investing activities 18,073 (41)
Cash flows from financing activities:    
Proceeds from issuances of common stock under benefit plans 484 376
Proceeds from issuance of common stock and pre-funded warrants from Private Placement 200,000 0
Payments of issuance costs for common stock and pre-funded warrants from Private Placement (169) 0
Net cash provided by financing activities 200,315 376
Net cash increase (decrease) for the period 196,360 (9,512)
Cash, cash equivalents and restricted cash at beginning of the period 59,006 252,213
Cash, cash equivalents and restricted cash at end of the period 255,366 242,701
Reconciliation of cash, cash equivalents and restricted cash to the balance sheet    
Cash and cash equivalents 254,366 241,701
Restricted cash 1,000 1,000
Total cash, cash equivalents and restricted cash 255,366 242,701
Supplemental disclosure of cash flow information:    
Purchases of equipment included in accounts payable and accrued and other current liabilities 9 0
Vesting of options early exercised subject to repurchase 17 32
Issuance costs for common stock and pre-funded warrants from Private Placement included in accounts payable and accrued liabilities $ 251 $ 0